Here are three things to know about the deal.
1. Cogentix manufactures various urology and endourology products. The company was formed via the merger of two devicemakers — Uroplasty and Vision-Sciences — in 2015, according to StarTribune.
2. Laborie, a urology health company, will acquire Cogentix for $3.85 per share, representing a 28 percent premium over the stock’s average closing price in the last 30 days.
3. Cogentix expects the deal to close in the second quarter of 2018.
More articles on supply chain:
Pfizer sells neurology drug to Biogen in nearly $600M deal: 4 things to know
4 latest FDA approval
FDA approves world’s smallest heart valve for newborns
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.